Skip to main content

Table 3 QoL score and VAS

From: The efficacy of alpha-1A blocker (tamsulosin), antimuscarinic (solifenacin) and their combination in the management of double-J stent-related lower urinary tract symptoms: a randomized controlled study

  Control Tamsulosin Solifenacin Combined therapy P-value
Median (Range) Median (Range) Median (Range) Median (Range)
QoL
Pre-insertion 0 (0–0) 0 (0–1) 0 (0–1) 0 (0–1) 0.31
After 2 weeks 5a,b,c (4–6) 3a,d (1–5) 3b,e (1–5) 2c,d,e (1–3) < 0.001
VAS
Pre-insertion 1 (0–2) 1 (0–2) 0 (0–1) 1 (0–2) 0.11
After 2 weeks 7a,b,c (4–9) 4a,d (3–6) 4b,e (2–5) 3c,d,e (1–5) 0.021
  1. Similar letters (a, b, c, d, e) indicate significant difference
  2. QoL Quality of life; VAS visual analog scale